In summary, based on available evidence, there is no additional increased risk of new or recurrent cancer with thiopurine, MTX, or biologic therapy, including anti-TNF and VDZ, in IBD patients with a history of previous cancer beyond the known risk in general IBD patients (without previous cancer). This evidence concerns the gene TNF and inflammatory bowel disease.